BioSpace News Archive

Collaboration with NYS Department of Health’s Wadsworth Center continues for extended six-month term until September 30, 2021 Project utilizes OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software within digital health and precision medicine platform at multiple healthcare institutions

Initial findings from the DEVOTE study suggest no new safety concerns and support continued development of a higher dose of SPINRAZA ® (nusinersen) Additional research reinforces the potential of biomarkers and highlights new digital tools that may help guide future treatment approaches and decisions for people with SMA

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Boston Business Journal (BBJ) has named Kymera Therapeutics to its 2021 Best Places to Work, an exclusive ranking of the Massachusetts companies that have built outstanding work environments for their people.

- - Seasoned healthcare executive, Brendan Smith, appointed as Chief Financial Officer, bringing strategic operations and financial leadership -- -- Appointments enhance capabilities across pulmonary programs, manufacturing and financial operations with a goal of advancing platform, preclinical and clinical milestones --

LifeMD, Inc. (“the Company”) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, today announced expected record revenue of $18.2M for Q1’21. The Company had previously guided towards revenue to be greater than $17 million (Link) . However, a stronger than expected March resulted in performance exceeding that guidance.

BioShin Limited, biopharmaceutical company focused on the discovery, development and commercialization of novel, life-improving treatments for patients with neuro-immune diseases in China and the Asia-Pacific region, today announced the appointment of David Chung as Chief Strategy Officer and Head of Business Development.

-- Multiple antigen constructs, including the construct used in MRT5500, induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies in multiple species -- -- Efficacy demonstrated in Syrian Golden Hamster challenge model under single and two-dose vaccination regimens of MRT5500 -- -- MRT5500 developed under a collaboration agreement with Sanofi Pasteur; Phase 1/2 clinical trial underway with clinical data anticipated in the third quarter of 2021 --

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will enter into a collaboration with the Duke Clinical Research Institute (DCRI) to support the clinical development of 9 Meters candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for short bowel syndrome (SBS).

StageZero Life Sciences (TSX:SZLS), a company dedicated to early detection of multiple disease states through whole blood, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL on Thursday April 22 at 8:30 AM EST.

Phase 1a/1b clinical trials beginning April 2021 will assess the safety and tolerability of ZYUS’ lead drug product candidate in healthy adult participants